BSE filing, NSE: GUJTHEM. Summary written from the filing by ALFA Finder's alert engine.
Gujarat Themis Biosyn Ltd: key numbers
- Share price
- ₹371.80
- Market cap
- ₹4,839 Cr
- Revenue (annual)
- ₹165.8 Cr
- Net profit (annual)
- ₹46.68 Cr
- P/E (TTM)
- 99.4×Sector 46.1×
- Promoter holding
- 59.33%-11.53% QoQ
- FII holding
- 3.80%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Themis Biosyn Ltd
All →Gujarat Themis Biosyn Board Meeting Date
Gujarat Themis Biosyn scheduled its board meeting for 4 Nov 2026 to approve Q2 and H2 un-audited results. No financial figures are disclosed in this advance intimation.
Gujarat Themis Biosyn Other Announcement
Gujarat Themis Biosyn clarified that its 9 October 2026 credit-rating intimation was uploaded in error and should be disregarded. No substantive business event is reported.
Gujarat Themis Biosyn Other Announcement
Gujarat Themis Biosyn Limited submitted the mandatory quarterly compliance certificate under SEBI Regulation 74(5) regarding dematerialization of shares for the quarter ended September 30, 2026.
Gujarat Themis Biosyn Annual General Meeting
Gujarat Themis Biosyn Ltd held its 45th Annual General Meeting on September 30, 2026, to deliberate on ordinary and special business resolutions.
Gujarat Themis Biosyn Annual General Meeting
Gujarat Themis Biosyn issued a corrigendum to its 45th AGM notice, updating the preferential issue resolution regarding share price, issue size, and allottee details.
Gujarat Themis Biosyn Acquisition Worth ₹1,300 Cr
Gujarat Themis Biosyn Limited acquired MicroBiopharm Japan Co. Ltd. for approximately ₹1,300 Crore. This acquisition expands its pharmaceutical CDMO capabilities.
- Value
- ₹1,300 Cr
Other other announcement announcements
All →Milky Mist Dairy Food Other Announcement
Milky Mist's board appointed B Chandra & Associates as Secretarial Auditors for FY 2026-27 to 2030-31. Shareholder approval is pending at the ensuing AGM.
- Execution
- FY 2026-27 to FY 2030-31 (five years)
Mahamaya Lifesciences Other Announcement
Mahamaya Lifesciences Ltd, an SME-platform listed company, confirms non-applicability of Corporate Governance under Regulation 27(2) for the quarter ended 30 September 2026. A Company Secretary certificate is enclosed.
Wipro Other Announcement
Wipro disclosed a designated person's 34,200-share ADR sale worth about ₹0.67 Crore on 28 October 2026. The sale followed RSU exercise, leaving 60,266 securities held.
- Value
- ₹0.67 Cr
OK Play India Other Announcement
OK Play India filed its quarterly shareholding pattern for the quarter ended September 2026. It shows category holdings only, with no transaction.
Spice Islands Industries Other Announcement
Spice Islands Industries filed a Reg 32 statement reporting no deviation in preferential issue fund utilization for Q3 FY27. The ₹8.70 Crore raise is fully deployed.
Setubandhan Infrastructure Other Announcement
RP informs exchanges that Setubandhan Infrastructure cannot file quarterly compliance documents due to depository fee non-payment. The company remains under CIRP with a pending NCLAT appeal.